- Home
- Publications
- Publication Search
- Publication Details
Title
Current Understanding of DDX41 Mutations in Myeloid Neoplasms
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 2, Pages 344
Publisher
MDPI AG
Online
2023-01-05
DOI
10.3390/cancers15020344
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
- (2022) Warren Fiskus et al. Blood Cancer Journal
- Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia
- (2022) Courtney D. DiNardo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prediction of survival with intensive chemotherapy in acute myeloid leukemia
- (2022) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
- (2022) Nicolas Duployez et al. BLOOD
- Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
- (2022) Musa Yilmaz et al. Blood Cancer Journal
- DDX41 is needed for pre- and postnatal hematopoietic stem cell differentiation in mice
- (2022) Jing Ma et al. Stem Cell Reports
- The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms
- (2022) Peng Li et al. BLOOD
- Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2022) Tapan M. Kadia et al. JOURNAL OF CLINICAL ONCOLOGY
- Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production
- (2021) Joshua T. Weinreb et al. DEVELOPMENTAL CELL
- Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia
- (2021) Eun-Ji Choi et al. HAEMATOLOGICA
- Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations
- (2021) Sarah A. Bannon et al. Frontiers in Oncology
- De novo acute myeloid leukemia: A population‐ based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017
- (2021) Koji Sasaki et al. CANCER
- Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax
- (2021) Curtis A. Lachowiez et al. Blood Advances
- Outcomes of TP53 ‐mutant acute myeloid leukemia with decitabine and venetoclax
- (2021) Kunhwa Kim et al. CANCER
- Outcomes in patients with newly diagnosed TP53 ‐mutated acute myeloid leukemia with or without venetoclax‐based therapy
- (2021) Sangeetha Venugopal et al. CANCER
- Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia
- (2021) Timothy M. Chlon et al. Cell Stem Cell
- Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy
- (2021) Koji Sasaki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
- (2021) Christopher J. Gibson et al. JOURNAL OF CLINICAL ONCOLOGY
- AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome
- (2021) Peng Li et al. LEUKEMIA
- Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms
- (2021) Hassan B. Alkhateeb et al. Blood Advances
- Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy
- (2020) Guillermo Montalban‐Bravo et al. AMERICAN JOURNAL OF HEMATOLOGY
- LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents
- (2020) Kelly S. Chien et al. LEUKEMIA & LYMPHOMA
- Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
- (2020) Abhishek Maiti et al. ACTA HAEMATOLOGICA
- Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations
- (2020) Shiqiang Qu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1
- (2020) Andrés E. Quesada et al. MODERN PATHOLOGY
- Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
- (2020) Iman Abou Dalle et al. Blood Cancer Journal
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
- (2020) Courtney D DiNardo et al. Lancet Haematology
- Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality
- (2020) Abhishek Maiti et al. AMERICAN JOURNAL OF HEMATOLOGY
- Genetic predisposition to MDS: clinical features and clonal evolution
- (2019) Alyssa L. Kennedy et al. BLOOD
- Prognostic Significance of Baseline FLT3 ‐ITD Mutant Allele Level in Acute Myeloid Leukemia Treated with Intensive Chemotherapy With/Without Sorafenib
- (2019) Fevzi Yalniz et al. AMERICAN JOURNAL OF HEMATOLOGY
- Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia
- (2019) Koji Sasaki et al. CANCER
- Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation
- (2019) Iman Abou Dalle et al. AMERICAN JOURNAL OF HEMATOLOGY
- Germline DDX41 mutations define a significant entity within adult MDS/AML patients
- (2019) Marie Sébert et al. BLOOD
- Impact of the variant allele frequency of ASXL1 , DNMT3A , JAK2 , TET2 , TP53 , and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia
- (2019) Koji Sasaki et al. CANCER
- Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes
- (2019) Guillermo Montalban-Bravo et al. LEUKEMIA
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels
- (2018) Courtney D. DiNardo et al. CANCER
- Pathogenic Germline Variants in 10,389 Adult Cancers
- (2018) Kuan-lin Huang et al. CELL
- Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
- (2018) Kiyomi Morita et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
- (2018) Nicholas J. Short et al. AMERICAN JOURNAL OF HEMATOLOGY
- Myeloid neoplasms with germline DDX41 mutation
- (2017) Jesse J. C. Cheah et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation
- (2017) S Kobayashi et al. LEUKEMIA
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents
- (2016) Elias Jabbour et al. CANCER
- Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia
- (2016) Moe Kadono et al. EXPERIMENTAL HEMATOLOGY
- Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation
- (2016) G Berger et al. LEUKEMIA
- Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
- (2016) E Negoro et al. LEUKEMIA
- Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia
- (2016) S R Cardoso et al. LEUKEMIA
- The emerging roles of the DDX41 protein in immunity and diseases
- (2016) Yan Jiang et al. Protein & Cell
- Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies
- (2015) M. Lewinsohn et al. BLOOD
- Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms
- (2015) Chantana Polprasert et al. CANCER CELL
- Bruton’s Tyrosine Kinase Phosphorylates DDX41 and Activates Its Binding of dsDNA and STING to Initiate Type 1 Interferon Response
- (2015) Koon-Guan Lee et al. Cell Reports
- The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells
- (2011) Zhiqiang Zhang et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started